Management of skin sarcoidosis with minocycline monotherapy

Shinichi Sasaki1, Motoyasu Kato1,2, Kota Nakamura1, Yukiko Namba1, Osamu Nagashima1 & Kazuhisa Takahashi2

1Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan. 2Department of Respiratory Medicine, Juntendo University, Graduate School of Medicine, Tokyo, Japan.

Keywords
Minocycline, monotherapy, Propionibacterium acnes, sarcoidosis, skin.

Abstract
A 46-year-old woman with severe skin sarcoidosis, mainly on the back of the trunk, persisting for >15 years, was followed up without systemic treatment. In 2014, she was started on minocycline monotherapy owing to worsening of the skin sarcoid lesions. Surprisingly, after approximately 1 year of the monotherapy, nearly all skin lesions resolved with only light residual scars, despite the poor efficacy of the monotherapy for pulmonary sarcoidosis. The patient’s serum angiotensin-converting enzyme levels also decreased to the normal range. The presence of Propionibacterium acnes was confirmed when a retrospectively immunostained epithelioid granuloma, obtained from skin biopsy, demonstrated staining with monoclonal antibodies specific for P. acnes. Minocycline monotherapy, thus, appears to be a possible treatment modality for skin sarcoidosis.

Introduction
Sarcoidosis is a systemic granulomatous disease of unknown origin; it leads to the formation of epithelioid granulomas without caseous necrosis in systemic organs and has various clinical symptoms. Although spontaneous remission occurs in many cases, the disease becomes intractable because of progression to the chronic state or repeated recurrence, which reportedly occurs in approximately 30% of patients. A common treatment strategy is to use immunosuppressive therapy, primarily corticosteroids. However, the long-term administration of corticosteroids causes many adverse events, which may also affect the therapy outcome. Although the cause of sarcoidosis remains unknown, Propionibacterium acnes, the only microorganism to be isolated and cultured from sarcoidosis lesions, has garnered attention as the most likely pathogenic bacterium [1]. Various antimicrobial agents have been used to eradicate P. acnes; particularly, minocycline is the most frequently used antimicrobial agent and has recently been reported to be effective for treating skin sarcoidosis [2]. We present a case in which the use of minocycline monotherapy resulted in the complete remission of skin sarcoidosis that had remained untreated without remission for 15 years.

Case Report
A 46-year-old woman with sarcoidosis was followed up at Juntendo Urayasu Hospital from May 1993 onward. Her chief complaint was visual disturbance due to uveitis, and steroid-containing eye drops were administered. On 14 March 1994, she visited the hospital complaining of sudden right visual disturbance along with a severe headache and was diagnosed with vitreous haemorrhage. She was admitted to our hospital for surgery on 9 May and started on oral steroid therapy with methylprednisolone (20 mg). On 12 May, she underwent vitrectomy combined with endoscopic photocoagulation surgery for her right eye, and the corticosteroid dose was gradually tapered off before being discontinued.

After the surgery, she was followed up without the oral steroid therapy. In early 1998, she developed some skin eruptions (resembling raised erythematous smooth plaques) on her back that continued to gradually progress (Fig. 1B). Skin biopsy performed on 14 April 1999 revealed
multiple granulomatous lesions, confirming a diagnosis of sarcoidosis (Fig. 2D). At that time, a chest computed tomography (CT) revealed diffused small nodules and consolidations in her lung field, indicating a pulmonary involvement of sarcoidosis. However, even after sarcoidosis was diagnosed, she refused oral corticosteroid therapy and was followed up without treatment. Her chest X-ray and CT findings were unremarkable, and the serum angiotensin-converting enzyme (ACE) level fluctuated between 25 and 32 U/mL (Fig. 1A). In early 2014, her skin eruptions became worse, and we decided to treat her skin sarcoidosis with minocycline monotherapy.

Notably, after the initiation of minocycline (11 April 2014), her skin eruptions, which had never improved in >15 years, started resolving gradually. The plaque redness decreased, the bulging started to heal (Fig. 1B), and her serum ACE level also decreased (Fig. 1A). After almost one year of the monotherapy, her skin sarcoid plaques almost disappeared with only slight scarring. Moreover, there was a marked decrease in her serum ACE level (from 24.7 to 13.6 U/L). Despite these significant improvements, the amelioration of pulmonary sarcoidosis was minimal. Over the last two years, the patient has continued to receive the minocycline monotherapy without any significant adverse events.

We retrospectively performed immunohistochemical staining on a skin biopsy (paraffin block specimen obtained on 14 April 1999) using a P. acnes-specific
monoclonal antibody (PAB antibody) that reacts with cell-membrane-bound lipoteichoic acid [3]. Notably, despite the absence of staining with anti-mycobacterium tuberculosis antibody, the PAB antibody stain was positive (Fig. 2D), revealing the presence of \textit{P. acnes} in the skin sarcoid granulomatous lesion.

**Discussion**

The most likely aetiology of sarcoidosis is an allergic reaction to a chronic persistent infection with \textit{P. acnes}, a pathogenic bacterium that causes acne vulgaris. \textit{P. acnes} invades from the external environment through the airway and causes subclinical infection. Sarcoidosis occurs only in individuals with excessive immunoreactions due to the intracellular proliferation of \textit{P. acnes} [1].

In our case, the patient had been followed up for 15 years without any treatment, and the minocycline monotherapy, without corticosteroids or other immunosuppressive agents, resulted in the resolution of skin lesions and decreased serum ACE levels. Moreover, PAB staining of a skin biopsy specimen confirmed the presence of \textit{P. acnes}. This result raises the question of whether the eradication of \textit{P. acnes} might have contributed to the remission. In that case, the minocycline monotherapy can be expected to be as effective for lung lesions as for skin lesions. However, in our patient, the improvement in the lung lesions was much lesser than that in the skin lesions.

The efficacy of antimicrobial agents on sarcoidosis has been reported in several studies. Bachelez et al. have reported the efficacy of minocycline for treating 12 patients with chronic skin sarcoidosis [2]. In their study, a 200 mg dose of minocycline was administered to 12 patients with chronic skin sarcoidosis for a median duration of 12 months, and complete and partial responses were observed in eight and two patients, respectively. Moreover, of the seven patients with complete responses who discontinued minocycline, three experienced relapse. Furthermore, in our patient, the effect of the antibiotic on the lung lesions was mostly poor. Minocycline is reportedly effective on ocular sarcoidosis lesions [4]. Recently, Takemori et al. have reported the use of clarithromycin to treat \textit{P. acnes} infection of the lymph nodes in patients with acute-onset sarcoidosis [5]. Their study suggested that remission results from clarithromycin-induced apoptosis through immunosuppression or immunomodulation.

Minocycline—a member of tetracyclines—has various immunomodulating properties; tetracyclines inhibit the migration and chemotaxis of leukocytes [6], whereas minocycline and doxycycline inhibit the activation and proliferation of T cells [7]. Additionally, minocycline and doxycycline inhibit granuloma formation [8]. Moreover,
the growing interest in minocycline has led to detailed evaluations of its therapeutic efficacy in many other experimental disease models, such as inflammatory bowel disease, diabetes, fragile X syndrome, cerebral ischaemia, and human immunodeficiency virus infection [1].

In the present case, it was assumed that the various non-antimicrobial activities of minocycline, including its immunomodulating activity, contributed to its efficacy on the skin lesions. The differences between its efficacy on skin and pulmonary lesions may also be attributable to the differences in the pathogenic mechanisms between the two organs. The further accumulation of cases and detailed studies are, therefore, warranted to elucidate the mechanism in detail.

Disclosure Statement
Appropriate written informed consent was obtained for publication of this case report and accompanying images.

Acknowledgments
We thank Yoshinobu Eishi (Chief Professor, Department of Human Pathology, Tokyo Medical and Dental University Graduate School) for immunohistochemical staining of the skin biopsy specimen and outstanding advice.

References
1. Eishi Y. 2013. Etiologic link between sarcoidosis and Propionibacterium acnes. Respir. Investig. 51:56–68.
2. Bachelez H, Senet P, Cadranel J, et al. 2001. The use of tetracyclines for the treatment of sarcoidosis. Arch. Dermatol. 137:69–73.
3. Negi M, Takemura T, Guzman J, et al. 2012. Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod. Pathol. 25:1284–1297.
4. Park DJ, Woog JJ, Pulido JS, et al. 2007. Minocycline for the treatment of ocular and ocular adnexal sarcoidosis. Arch. Ophthalmol. 125:705–709.
5. Takemori N, Nakamura M, Kojima M, et al. 2014. Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report. J Med Case Reports 8:15.
6. Esterly NB, Koransky JS, Furey NL, et al. 1984. Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy. Arch. Dermatol. 120:1308–1313.
7. Kloppenburg M, Verweij CL, Miltenburg AM, et al. 1995. The influence of tetracyclines on T cell activation. Clin. Exp. Immunol. 102:635–641.
8. Webster GF, Toso SM, and Hegemann L. 1994. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch. Dermatol. 130:748–752.